Connor Clark & Lunn Investment Management Ltd. Has $723,000 Stock Holdings in Definitive Healthcare Corp. $DH

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Definitive Healthcare Corp. (NASDAQ:DH - Free Report) by 70.6% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 250,152 shares of the company's stock after buying an additional 103,529 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned 0.23% of Definitive Healthcare worth $723,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Bayesian Capital Management LP bought a new position in Definitive Healthcare during the fourth quarter worth about $41,000. Two Sigma Securities LLC bought a new position in Definitive Healthcare during the fourth quarter worth about $56,000. ProShare Advisors LLC lifted its stake in Definitive Healthcare by 49.1% during the fourth quarter. ProShare Advisors LLC now owns 15,018 shares of the company's stock worth $62,000 after purchasing an additional 4,943 shares during the period. Cerity Partners LLC bought a new position in Definitive Healthcare during the first quarter worth about $56,000. Finally, Price T Rowe Associates Inc. MD lifted its stake in Definitive Healthcare by 20.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 20,572 shares of the company's stock worth $85,000 after purchasing an additional 3,496 shares during the period. 98.67% of the stock is owned by institutional investors and hedge funds.

Definitive Healthcare Trading Up 1.6%

Shares of NASDAQ:DH opened at $3.93 on Tuesday. The company's 50-day moving average price is $3.92 and its two-hundred day moving average price is $3.56. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.65 and a quick ratio of 1.65. Definitive Healthcare Corp. has a one year low of $2.15 and a one year high of $5.68. The stock has a market capitalization of $562.54 million, a PE ratio of -1.48, a price-to-earnings-growth ratio of 6.51 and a beta of 1.64.

Analyst Ratings Changes

A number of research analysts have recently issued reports on DH shares. BTIG Research cut shares of Definitive Healthcare from a "buy" rating to a "neutral" rating in a research note on Friday, May 9th. The Goldman Sachs Group lifted their target price on shares of Definitive Healthcare from $3.00 to $3.40 and gave the company a "neutral" rating in a research note on Monday, May 12th. Wall Street Zen upgraded shares of Definitive Healthcare from a "hold" rating to a "buy" rating in a research note on Saturday, June 21st. Stifel Nicolaus lifted their target price on shares of Definitive Healthcare from $5.00 to $6.00 and gave the company a "buy" rating in a research note on Friday, August 8th. Finally, Robert W. Baird set a $4.00 price target on shares of Definitive Healthcare in a report on Friday, August 8th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $4.73.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.

Want to see what other hedge funds are holding DH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Definitive Healthcare Corp. (NASDAQ:DH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.